Albus Imaging Cardioprotection for Cancer Patients

 描述(申请人提供)：ALBUS影像社区医院在癌症治疗期间识别高心血管风险患者项目摘要/摘要：这项研究的目标是使社区医院能够使用我们先进的心脏磁共振成像(MRI)程序尽早发现乳腺癌患者的心血管损伤。这一点非常重要，因为1)近20%的乳腺癌幸存者将经历严重的心脏事件，2)这些患者中的大多数在社区医院接受治疗，目前这些社区医院无法获得这些先进的成像技术。我们的快速心脏成像采集和分析过程克服了阻碍心脏MRI临床广泛应用的几个限制，包括采集和分析图像所需的相对较高水平的培训，以及长达45分钟的扫描和分析时间。将这项技术引入社区医院将使我们公司能够朝着另一个总体目标努力：识别最容易受到心脏损伤的女性，这样她们就可以接受心脏保护疗法，以减少心血管损伤并提高总体存活率。在这份第一阶段的提案中，我们将比较在五家社区医院接受乳腺癌治疗的女性患者中，OU快速磁共振成像(MRI)扫描、分析和预测过程与更传统的技术(如常规45分钟MRI、超声心动图和心脏血液测试)的实用性。如果这项第一阶段研究成功，我们将在全国15家社区医院接受治疗的妇女中推广和测试该产品。我们相信，这项先进的技术可以帮助和扩展用于许多其他有潜在心血管损伤风险的患者，如其他癌症患者、糖尿病患者和那些有其他心力衰竭原因的患者。

 DESCRIPTION (provided by applicant): Albus Imaging Community hospital identification of high CV risk patients during cancer treatment Project Summary/Abstract: The goal of this research is to enable community hospitals to detect cardiovascular injury very early in breast cancer patients using our advanced cardiac magnetic resonance imaging (MRI) procedures. This is very significant because 1) nearly 20% of breast cancer survivors will experience a serious cardiac event and 2) most of these patients are treated in community hospital settings that do not currently have access to these advanced imaging techniques. Our rapid cardiac imaging acquisition and analysis process overcomes several of the limitations that have prevented the widespread clinical utilization of cardiac MRI, including the relatively high level o training necessary to acquire and analyze the images, and the lengthy 45+ minute scan and analysis times. Introducing this technology to community hospitals will allow our company to work toward another one of its overall goals: to identify the women most susceptible to cardiac injury so they can be targeted with cardioprotective regimens to reduce cardiovascular injury and improve overall survival. Initially in this Phase I proposal, we will compare the utility of ou rapid magnetic resonance imaging (MRI) scan, analysis, and forecasting process with the more traditional techniques, such as, conventional 45-minute MRI, echocardiography, and cardiac blood tests in women receiving treatment for breast cancer in five community hospitals. If this Phase I study is successful, we will expand and test the product in women treated among 15 community hospitals nationwide. We believe that this advanced technique can be helpful and scaled for use in many other patients at risk for potential CV injury such as other cancer patients, diabetics and those with other causes of heart failure.